A Study of LY3502970 in Participants With Impaired and Normal Liver Function

Be Men or women with body weight of at least 45 kilograms and a body mass index of 18.5 to 40.0 kilograms per meter squared (kg/m²)

Participants must have a diagnosis of chronic hepatic impairment for more than 6 months per physician diagnosis

Participants with acceptable BP and pulse rate

Participants with no significant history of spontaneous or ethanol induced hypoglycemia

Have T2DM controlled with diet or exercise alone or on stable doses of anti-diabetic medication metformin or sulfonylureas, for at least 8 weeks prior to screening

Participants with Mild to Severe Hepatic Impairment who have a hemoglobin level of at least 8.5 grams/decilitre

Participants with both T2DM and Hepatic Impairment have a hemoglobin A1c greater than or equal to 5.0% and less than or equal to 11.0% at the screening visit

Participants with both T2DM and Hepatic Impairment have clinical laboratory test results within normal range

Participants with any abnormality in the 12-lead ECG at screening

Participants with severe atopy or have a history of clinically significant multiple or severe drug allergies or severe post treatment hypersensitivity reactions

Have a history of, or current psychiatric disorders

Women who are pregnant, intend to become pregnant or are breastfeeding a child are not eligible to participate

Have taken any glucose-lowering medications other than metformin, sulfonylureas, and insulin, in the past 6 weeks or 5 half-lives (whichever is longer) prior to planned dosing